STOCK TITAN

Bio-Rad executive granted 2,876 restricted stock units

Bio-Rad’s EVP and general counsel received new RSU awards and had prior RSUs vest into Class A shares, with a portion of shares withheld for taxes.

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BIO-RAD LABORATORIES, INC. (BIO) reported that executive vice president and general counsel Courtney C. Enloe received and settled equity awards in Bio-Rad Class A common stock. On September 4, 2026, Enloe was granted 2,876 restricted stock units, each representing a contingent right to one Class A share, vesting over four years. On September 5 and 6, 2026, a total of 1,453 restricted stock units vested and were converted into an equal number of Class A shares; 551 shares were delivered or withheld at $386.11 per share for payment of exercise price or tax liability. No Rule 10b5-1 plan is reported.

Positive

  • None.

Negative

  • None.
Insider ENLOE COURTNEY C
Role EVP, General Counsel & Sec
Type Security Shares Price Value
Exercise Restricted Stock Units F2, F4 768 $0.00 $0.00
Exercise Bio-Rad A Common Stock F1 768 $0.00 $0.00
Exercise Price or Tax Liability Bio-Rad A Common Stock 305 $386.11 $118K
Exercise Restricted Stock Units F2, F4 685 $0.00 $0.00
Exercise Bio-Rad A Common Stock F1 685 $0.00 $0.00
Exercise Price or Tax Liability Bio-Rad A Common Stock 246 $386.11 $95K
Grant/Award Restricted Stock Units F2, F3 2,876 $0.00 $0.00
Holdings After Transaction: Restricted Stock Units — 6,467 contracts (Direct); Bio-Rad A Common Stock — 1,651.777 shares (Direct)
Footnotes (4)
  1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
  2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  3. F3. The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
  4. F4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
RSU grant 2,876 units Restricted stock units granted on September 4, 2026
RSUs vested 1,453 units Restricted stock units vested and converted on September 5–6, 2026
Shares withheld 551 shares Shares delivered or withheld for payment of exercise price or tax liability
Withholding price $386.11 per share Price used for shares delivered or withheld for exercise price or tax liability
Derivative exercises 2 transactions M-code exercises or conversions of RSUs on September 5–6, 2026
Code F dispositions 551 shares Two F-code transactions for exercise price or tax liability
Restricted Stock Units financial
"Shares of Class A common stock acquired on the vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
vest financial
"The restricted stock units vest over four years, with 25% vesting on the first anniversary"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercise price or tax liability financial
"Payment of exercise price or tax liability by delivering or withholding securities"

FAQ

What equity awards did BIO executive Courtney Enloe receive in this Form 4?

Courtney C. Enloe received 2,876 restricted stock units on September 4, 2026, each representing a contingent right to receive one share of Bio-Rad Class A common stock, vesting over four years with 25% at the first anniversary and the remainder in equal quarterly installments.

How many Bio-Rad (BIO) RSUs vested for Courtney Enloe and when?

A total of 1,453 restricted stock units vested for Courtney C. Enloe, converting into the same number of Bio-Rad Class A shares on September 5, 2026 (685 RSUs) and September 6, 2026 (768 RSUs), pursuant to the award vesting schedules.

How many BIO shares were withheld for taxes or exercise price in this filing?

The company reports that 551 shares of Bio-Rad Class A common stock (305 shares on September 6, 2026, and 246 shares on September 5, 2026) were delivered or withheld at $386.11 per share for payment of exercise price or tax liability.

Was a Rule 10b5-1 trading plan used for Courtney Enloe’s BIO transactions?

No. The filing indicates that the Rule 10b5-1 checkbox is not marked for these transactions, so no Rule 10b5-1 trading plan is reported in connection with the Form 4 filed for Courtney C. Enloe.

What is the vesting schedule of the new RSUs reported by BIO?

The new restricted stock units reported for Courtney C. Enloe vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter, as disclosed in the footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ENLOE COURTNEY C

(Last)(First)(Middle)
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE

(Street)
HERCULES CALIFORNIA 94547

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
EVP, General Counsel & Sec
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Bio-Rad A Common Stock09/05/2026M685(1)A$01,434.777D
Bio-Rad A Common Stock09/05/2026F246D$386.111,188.777D
Bio-Rad A Common Stock09/06/2026M768(1)A$01,956.777D
Bio-Rad A Common Stock09/06/2026F305D$386.111,651.777D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$0(2)09/04/2026A2,876 (3) (3)Bio-Rad A Common Stock2,876$02,876D
Restricted Stock Units$0(2)09/05/2026M685 (4) (4)Bio-Rad A Common Stock685$02,055D
Restricted Stock Units$0(2)09/06/2026M768 (4) (4)Bio-Rad A Common Stock768$01,536D
Explanation of Responses:
1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. The restricted stock units vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining units vesting in equal quarterly installments thereafter.
4. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Remarks:
/s/ Courtney C. Enloe09/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading